National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1-Full Report

被引：810

作者：

Jacobson, Terry A. ^{[1
]}

Ito, Matthew K. ^{[2
]}

Maki, Kevin C. ^{[3
,4
]}

Orringer, Carl E. ^{[5
]}

Bays, Harold E. ^{[6
]}

Jones, Peter H. ^{[7
]}

McKenney, James M. ^{[8
,9
]}

Grundy, Scott M. ^{[10
]}

Gill, Edward A. ^{[11
]}

Wild, Robert A. ^{[12
]}

Wilson, Don P. ^{[13
]}

Brown, W. Virgil ^{[14
]}

机构：

[1] Emory Univ Sch Med, Dept Med, Atlanta, GA USA

[2] Oregon Hlth & Sci Univ, Oregon State Univ, Coll Pharm, Portland, OR 97201 USA

[3] Midwest Ctr Metab & Cardiovasc Res, Chicago, IL USA

[4] Depaul Univ, Chicago, IL 60604 USA

[5] Univ Miami Hlth Syst, Miami, FL USA

[6] Louisville Metab & Atherosclerosis Res Ctr, Louisville, KY USA

[7] Baylor Coll Med, Houston, TX 77030 USA

[8] Virginia Commonwealth Univ, Richmond, VA USA

[9] Natl Clin Res, Richmond, VA USA

[10] Univ Texas SW Med Ctr Dallas, Dallas, TX USA

[11] Univ Washington, Harborview Med Ctr, Seattle, WA 98195 USA

[12] Oklahoma Univ Hlth Sci Ctr, Oklahoma City, OK USA

[13] Cook Childrens Med Ctr, Ft Worth, TX USA

[14] Emory Univ Sch Med, Atlanta, GA USA

来源：

JOURNAL OF CLINICAL LIPIDOLOGY | 2015年 / 9卷 / 02期

关键词：

Clinical recommendations; Dyslipidemia; Atherogenic cholesterol; Low-density lipoprotein cholesterol; Lipoproteins; Atherosclerotic cardiovascular disease; Coronary heart disease; DENSITY-LIPOPROTEIN CHOLESTEROL; CORONARY-HEART-DISEASE; NON-HDL CHOLESTEROL; TRIGLYCERIDE-RICH LIPOPROTEINS; NUCLEAR-MAGNETIC-RESONANCE; APOLIPOPROTEIN-B LEVELS; HIGH-DOSE ATORVASTATIN; ALL-CAUSE MORTALITY; RISK-FACTOR BURDEN; INCIDENT CARDIOVASCULAR EVENTS;

D O I：

10.1016/j.jacl.2015.02.003

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

The leadership of the National Lipid Association convened an Expert Panel to develop a consensus set of recommendations for patient-centered management of dyslipidemia in clinical medicine. An Executive Summary of those recommendations was previously published. This document provides support for the recommendations outlined in the Executive Summary. The major conclusions include (1) an elevated level of cholesterol carried by circulating apolipoprotein B-containing lipoproteins (non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol [LDL-C], termed atherogenic cholesterol) is a root cause of atherosclerosis, the key underlying process contributing to most clinical atherosclerotic cardiovascular disease (ASCVD) events; (2) reducing elevated levels of atherogenic cholesterol will lower ASCVD risk in proportion to the extent that atherogenic cholesterol is reduced. This benefit is presumed to result from atherogenic cholesterol lowering through multiple modalities, including lifestyle and drug therapies; (3) the intensity of risk-reduction therapy should generally be adjusted to the patient's absolute risk for an ASCVD event; (4) atherosclerosis is a process that often begins early in life and progresses for decades before resulting a clinical ASCVD event. Therefore, both intermediate-term and long-term or lifetime risk should be considered when assessing the potential benefits and hazards of risk-reduction therapies; (5) for patients in whom lipid-lowering drug therapy is indicated, statin treatment is the primary modality for reducing ASCVD risk; (6) nonlipid ASCVD risk factors should also be managed appropriately, particularly high blood pressure, cigarette smoking, and diabetes mellitus; and (7) the measurement and monitoring of atherogenic cholesterol levels remain an important part of a comprehensive ASCVD prevention strategy. (C) 2015 National Lipid Association. All rights reserved.

引用

页码：129 / 169

页数：41

共 344 条

[1]

Agrawal M, 2010, J INVEST MED, V58, P945, DOI 10.231/JIM.0b013e3181fb7ca7

[2]

Acute coronary syndromes and diabetes: is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial [J].